• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Premature Ventricular Complexes on Screening Electrocardiogram and Risk of Ischemic Stroke Brief Reports
Conclusions— PVCs are common on routine screening ECGs and are associated with an increased risk of ischemic stroke.
Source: Stroke - April 27, 2015 Category: Neurology Authors: Agarwal, S. K., Chao, J., Peace, F., Judd, S. E., Kissela, B., Kleindorfer, D., Howard, V. J., Howard, G., Soliman, E. Z. Tags: Electrocardiology, Embolic stroke, Epidemiology Brief Reports Source Type: research

Non-vitamin-K oral anticoagulants reduce mortality, stroke and intracranial haemorrhage when compared with warfarin in randomised trials of patients with non-valvular atrial fibrillation
Commentary on: Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62. Context Historically, the standard medication for stroke prevention in atrial fibrillation (AF) has been a vitamin-K antagonist (warfarin). However, several non-vitamin-K oral anticoagulants (NOACs) have been developed and shown to be at least as effective as dose-adjusted warfarin in their respective phase-3 clinical trials.1–4 These include the direct thrombin inhibitor dabig...
Source: Evidence-Based Medicine - September 15, 2014 Category: Internal Medicine Authors: Steinberg, B. A. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Connective tissue disease, Musculoskeletal syndromes, Diabetes, Arrhythmias Therapeutics Source Type: research

Relation of Left Atrial Dysfunction to Ischemic Stroke in Patients With Coronary Heart Disease (from the Heart and Soul Study)
In conclusion, LA dysfunction is an independent risk factor for stroke or TIA, even in patients without baseline AF.
Source: The American Journal of Cardiology - March 5, 2014 Category: Cardiology Authors: Jonathan M. Wong, Christine C. Welles, Farnaz Azarbal, Mary A. Whooley, Nelson B. Schiller, Mintu P. Turakhia Tags: Arrhythmias and Conduction Disturbances Source Type: research

Antithrombotic therapy for ischaemic stroke patients with AF/RHD in West China daily practice.
CONCLUSION: Our study suggests that overall real-world use of warfarin in IS patients with AF and/or RHD is low before and after admission in West China. Implementation study on this respect should be conducted in this area to improve the daily practice. PMID: 26178783 [PubMed - as supplied by publisher]
Source: Neurological Research - July 17, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Get Rid of Toxins to Reduce Risk of Stroke
Effects of Toxins I’ve been warning you about the toxins in our environment for years. They cause inflammation… They make you gain weight… They cause you to feel fatigued… Our exposure to them starts before we’re even born. One study found 287 chemicals and toxins in the blood of newborn babies.1 It’s shocking. What is in the air we breathe? We breathe in toxins and air pollutants every day. Carbon dioxide, lead, nitrogen oxide, sulfur dioxide, and particulate matter (PM). Causes of Stroke Now, a new study reveals that air pollution is responsible for as many as one-third of all strokes.2 That’...
Source: Al Sears, MD Natural Remedies - July 15, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Health Source Type: news

Evaluation of Stroke Incidence with Duty ‐Cycled Multielectrode Phased Radio‐Frequency Ablation of Persistent Atrial Fibrillation Results of the VICTORY AF STUDY
ConclusionsVICTORY AF demonstrated a 1.6% incidence of stroke in PersAF undergoing ablation with a phased RF system which did not meet statistical confidence due to poor enrollment. The secondary outcomes suggest comparable efficacy to phased RF in the TTOP trial. Rigorous clinical evaluation of the stroke risk of new AF ablation technologies as well as restriction to VK ‐antagonist anti‐coagulation appear to be unachievable goals in a clinical multi‐center IDE trial of AF ablation in the current era.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - April 8, 2020 Category: Cardiology Authors: John Hummel, Atul Verma, Hugh Calkins, Lee H. Schwamm, Daryl Gress, Darryl Wells, Joseph Souza, Robert B Hokanson, Lauren Hemingway, Kurt Stromberg, Robert Hoyt, Andrew Wickliffe, David DeLurgio, Lucas Boersma Tags: ORIGINAL ARTICLE Source Type: research

Evaluation of stroke incidence with duty ‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study
ConclusionsVICTORY AF demonstrated a 1.6% incidence of stroke in PersAF undergoing ablation with a phased RF system which did not meet statistical confidence due to poor enrollment. The secondary outcomes suggest comparable efficacy to phased RF in the tailored treatment of permanent AF trial. Rigorous clinical evaluation of the stroke risk of new AF ablation technologies as well as restriction to Vitamin K antagonist anticoagulation appears to be unachievable goals in a clinical multicenter IDE trial of AF ablation in the current era.
Source: Journal of Cardiovascular Electrophysiology - April 23, 2020 Category: Cardiology Authors: John Hummel, Atul Verma, Hugh Calkins, Lee H. Schwamm, Daryl Gress, Darryl Wells, Joseph Souza, Robert B. Hokanson, Lauren Hemingway, Kurt Stromberg, Robert Hoyt, Andrew Wickliffe, David DeLurgio, Lucas Boersma Tags: ORIGINAL ARTICLE Source Type: research

Edoxaban for the prevention of stroke in patients with atrial fibrillation.
Authors: Cervantes CE, Merino JL, Barrios V Abstract INTRODUCTION: Edoxaban is the last direct oral anticoagulant marketed for the prevention of stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF-TIMI 48 was the pivotal clinical trial that led to the approval of edoxaban 60 mg once daily. After the publication of this study, a great number of substudies and post hoc analyses have been published, together with some observational studies. The aim of this review was to update the current evidence about the use of edoxaban in AF patients. Expert commentary: In the ENGAGE AF-TIMI 4...
Source: Expert Review of Cardiovascular Therapy - March 24, 2019 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Prognostic Value of Serum N-Terminal Pro-Brain Natriuretic Peptide Level over Heart Failure for Stroke Events and Deaths in Patients with Atrial Fibrillation.
Authors: Kuronuma K, Okumura Y, Morikawa T, Yokoyama K, Matsumoto N, Tachibana E, Oiwa K, Matsumoto M, Kojima T, Haruta H, Nomoto K, Sonoda K, Arima K, Kogawa R, Takahashi F, Kotani T, Ohkubo K, Fukushima S, Itou S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A, SAKURA AF Registry Investigators Abstract Atrial fibrillation (AF) and heart failure (HF) often coexist. The aims of this study were to explore the factors associated with the serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), and the association between prognosis and a history of HF or the serum NT-proBNP level in Japanese patients wit...
Source: International Heart Journal - May 20, 2020 Category: Cardiology Tags: Int Heart J Source Type: research

Laboratory characteristics of ischemic stroke patients with atrial fibrillation on or off therapeutic warfarin
ConclusionsAF patients who presented with IS on therapeutic warfarin had higher average serum creatinine and blood urea nitrogen, and lower glomerular filtration rates, compared with others. Impaired renal function may be a factor contributing to occurrence of IS in AF patients despite adequate anticoagulation. Larger, targeted studies are needed to confirm these findings.
Source: Clinical Cardiology - November 1, 2017 Category: Cardiology Authors: Raghav V. Aachi, Lee A. Birnbaum, Christopher H. Topel, Ali Seifi, Shaheryar Hafeez, R éza Behrouz Tags: CLINICAL INVESTIGATIONS Source Type: research

Pre-stroke warfarin enhancement of collateralization in acute ischemic stroke: a retrospective study
Warfarin therapies not only are used to prevent stroke in patients with high risk of cardioembolism such as patients with atrial fibrillation (AF) and rheumatic heart disease (RHD), but also was associated wit...
Source: BMC Neurology - November 29, 2018 Category: Neurology Authors: Jiaying Zhu, Mengmeng Ma, Yijia Guo, Muke Zhou, Jian Guo and Li He Tags: Research article Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pages: 1  2  3  4